학술논문
Kidney Histopathology Can Predict Kidney Function in ANCA-Associated Vasculitides with Acute Kidney Injury Treated with Plasma Exchanges
Document Type
Article
Author
Nezam, Dorian; Porcher, Rapha?l; Grolleau, Fran?ois; Morel, Pauline; Titeca-Beauport, Dimitri; Faguer, Stanislas; Karras, Alexandre; Solignac, Justine; Jourde-Chiche, No?mie; Maurier, Fran?ois; Sakhi, Hamza; El Karoui, Khalil; Mesbah, Rafik; Carron, Pierre Louis; Audard, Vincent; Ducloux, Didier; Paule, Romain; Augusto, Jean-Fran?ois; Aniort, Julien; Tiple, Aur?lien; Rafat, C?dric; Beaudreuil, S?verine; Pu?chal, Xavier; Gobert, Pierre; Massy, Ziad; Hanrotel, Catherine; Bally, St?phane; Martis, Nihal; Durel, C?cile-Audrey; Desbuissons, Geoffroy; Godmer, Pascal; Hummel, Aur?lie; Perrin, Fran?ois; N?el, Antoine; De Moreuil, Claire; Goulenok, Tiphaine; Guerrot, Dominique; Grange, Steven; Foucher, Aur?lie; Deroux, Alban; Cordonnier, Carole; Guilbeau-Frugier, C?line; Modesto-Segonds, Anne; Nochy, Dominique; Daniel, Laurent; Moktefi, Anissa; Rabant, Marion; Guillevin, Lo?c; R?gent, Alexis; Terrier, Benjamin
Source
Journal of the American Society of Nephrology; March 2022, Vol. 33 Issue: 3 p628-637, 10p
Subject
Language
ISSN
10466673; 15333450
Abstract
Findings of the international prospective multicenter PEXIVAS trial challenge the role of PLEX in AAV. We conducted a retrospective study of 425 patients: 188 with AAV and renal failure treated with PLEX and 237 not treated. A score to identify patients who would benefit from PLEX was developed. With kidney biopsy data, scores more than seven achieved sensitivity and specificity of 83.1% and 96.0%, respectively, for recommending PLEX. The average effect of PLEX for those with recommended treatment corresponded to an absolute risk reduction for death or KRT at M12 of 24.6%. Patients in the PLEX-recommended group had microscopic polyangiitis, MPO-ANCA, higher serum creatinine, crescentic and sclerotic classes, and higher Brix score. These findings, which require independent validation, could provide guidance in selecting patients with AAV who will benefit from PLEX.